Tokyo, Japan, June 18, 2015 – Sosei Group Corporation (“Sosei”; TSE Mothers Index:4565) confirms the plan to be announced later today by Novartis at a “Meet Novartis Management” investor event in Boston, USA to develop a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medication.
QVM149 is a fixed dose, once daily combination of the long-acting beta2-agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the inhaled corticosteroid (ICS) mometasone fuorate.
First regulatory filings of QVM149 are planned for 2018.
Glycopyrronium bromide was licensed exclusively to Novartis in April 2005 by Sosei and its co-development partner Vectura.
Under the terms of the Licence Agreement, Sosei is eligible to receive development, filing and approval milestones. In addition, Sosei will receive royalties on QVM149 sales in the event of a successful product launch.